NCT01281592View on ClinicalTrials.gov

A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

July 31, 2013

Study Completion Date

January 31, 2014

Conditions
Advanced or Metastatic Solid Tumours
Interventions
DRUG

LOR-253 HCl

LOR-253 HCl will be given in ascending doses starting from 20 mg/m2 until the maximum administered dose or appropriate target dose is reached. Patient will be treated on LOR-253 HCl for 2 cycles for the evaluation.

Trial Locations (2)

10065

Memorial Sloan-Kettering Cancer Center, New York

77030

MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

Aptose Biosciences Inc.

INDUSTRY